Turku, Finland – 12 July 2024: DelSiTech Ltd, a clinical stage Finnish drug delivery technology and development company announced today that Mr. Carl-Åke Carlsson has been appointed to its Board of Directors, effective as of June 19, 2024.
Mr. Carlsson has over three decades of global pharma business leadership experience in Nordic and international pharmaceutical companies. He is the former Chef Executive Officer of Xellia Pharmaecuticals, a mid-sized, Denmark and USA -based active substance manufacturing and specialty pharmaceuticals company. Prior to this CEO role, Mr. Carsson held several top-leadership roles in a US-stock listed generic pharma company Alpharma. Currently, Mr. Carlsson is serving at the Chairman of the Board positions in two Nordic pharma and biotech companies, Zerion Pharma in Denmark and Vectron Biosolutions in Norway.
“We are very pleased to welcome Carl-Åke Carlsson to DelSiTech,” said Dr. Örjan Andersson, Chairman of DelSiTech’s Board of Directors. “Mr. Carlsson has an extensive international career in the pharma industry and a deep understanding of B2B strategies and operations worldwide. He brings to our Board a vast experience and knowledge of global expansion and partnerships, helping DelSiTech to reach its strategic goals in the next few years.”
“I’m very impressed on the achievements that DelSiTech has made so far and truly believe in the huge potential that DelSiTech’s technology has in the drug delivery field,” said Mr. Carlsson. “I’m very confident in the company’s prospects, and I look forward to contributing to the success of DelSiTech.”
Turku, Finland – 12 July 2023: DelSiTech Ltd, a clinical stage Finnish drug delivery technology and development company announced today that Mr. Carl-Åke Carlsson has been appointed to its Board of Directors, effective as of June 19, 2024.
Mr. Carlsson has over three decades of global pharma business leadership experience in Nordic and international pharmaceutical companies. He is the former Chef Executive Officer of Xellia Pharmaecuticals, a mid-sized, Denmark and USA -based active substance manufacturing and specialty pharmaceuticals company. Prior to this CEO role, Mr. Carsson held several top-leadership roles in a US-stock listed generic pharma company Alpharma. Currently, Mr. Carlsson is serving at the Chairman of the Board positions in two Nordic pharma and biotech companies, Zerion Pharma in Denmark and Vectron Biosolutions in Norway.
“We are very pleased to welcome Carl-Åke Carlsson to DelSiTech,” said Dr. Örjan Andersson, Chairman of DelSiTech’s Board of Directors. “Mr. Carlsson has an extensive international career in the pharma industry and a deep understanding of B2B strategies and operations worldwide. He brings to our Board a vast experience and knowledge of global expansion and partnerships, helping DelSiTech to reach its strategic goals in the next few years.”
“I’m very impressed on the achievements that DelSiTech has made so far and truly believe in the huge potential that DelSiTech’s technology has in the drug delivery field,” said Mr. Carlsson. “I’m very confident in the company’s prospects, and I look forward to contributing to the success of DelSiTech.”